It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Histone variant H2A.Z is a conserved feature of nucleosomes flanking protein-coding genes. Deposition of H2A.Z requires ATP-dependent replacement of nucleosomal H2A by a chromatin remodeler related to the multi-subunit enzyme, yeast SWR1C. How these enzymes use ATP to promote this nucleosome editing reaction remains unclear. Here we use single-molecule and ensemble methodologies to identify three ATP-dependent phases in the H2A.Z deposition reaction. Real-time analysis of single nucleosome remodeling events reveals an initial priming step that occurs after ATP addition that involves a combination of both transient DNA unwrapping from the nucleosome and histone octamer deformations. Priming is followed by rapid loss of histone H2A, which is subsequently released from the H2A.Z nucleosomal product. Surprisingly, rates of both priming and the release of the H2A/H2B dimer are sensitive to ATP concentration. This complex reaction pathway provides multiple opportunities to regulate timely and accurate deposition of H2A.Z at key genomic locations.
The multi-subunit SWR1C remodeler deposits histone variant H2A.Z at nucleosomes flanking protein-coding genes. Here the authors use single-molecule and ensemble methodologies to identify three ATP-dependent phases in the H2A.Z deposition reaction.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 University of Massachusetts Chan Medical School, Program in Molecular Medicine, Worcester, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364); University of Massachusetts Chan Medical School, Interdisciplinary Graduate Program, Worcester, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364)
2 Blavatnik Institute, Harvard Medical School, Department of Biological Chemistry and Molecular Pharmacology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
3 University of Massachusetts Chan Medical School, Program in Molecular Medicine, Worcester, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364); University of Massachusetts Chan Medical School, Medical Scientist Training Program, Worcester, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364)
4 University of Massachusetts Chan Medical School, Program in Molecular Medicine, Worcester, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364)